TDP-43 Pathology in Corticobasal Syndrome

TDP-43 Pathology in Corticobasal Syndrome

Overview

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS["@murakami2025"].

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

TDP-43 Pathology in Corticobasal Syndrome

Overview

While corticobasal syndrome (CBS) is classically characterized as a 4-repeat (4R) tauopathy, a significant subset of cases exhibit TDP-43 pathology. This overlap between tauopathies and TDP-43 proteinopathies has important implications for understanding disease heterogeneity, clinical presentation, and therapeutic approaches. Research from 2025, including studies by Murakami et al., has clarified the frequency and significance of TDP-43 pathology in CBS["@murakami2025"].

TDP-43 Pathology in CBS: Current Understanding

Frequency and Distribution

TDP-43 pathology in CBS is more common than traditionally recognized:

| Pathological Category | Percentage of CBS Cases |
|---------------------|------------------------|
| Pure 4R tauopathy (no TDP-43) | ~50-60% |
| Mixed tau + TDP-43 pathology | ~25-35% |
| TDP-43 predominant | ~10-15% |

The distribution of TDP-43 pathology in CBS includes:

• Motor cortex (especially layer II)
• Basal ganglia (putamen, globus pallidus)
• Substantia nigra
• Hippocampus (in cases with cognitive impairment)
• Spinal cord anterior horns

Clinical Correlations

The presence of TDP-43 pathology influences the clinical presentation of CBS[@murakami2025]:

TDP-43 Inclusion Types in CBS

TDP-43 pathology in CBS manifests in multiple inclusion types, similar to those observed in other TDP-43 proteinopathies but with some distinct features.

Neuronal Cytoplasmic Inclusions (NCIs)

The most common TDP-43 inclusion type in CBS are neuronal cytoplasmic inclusions[@murakami2025]:

• Morphology: Round to oval, often with halo appearance
• Distribution: Predominantly in motor cortex, basal ganglia, and brainstem
• Composition: Hyperphosphorylated, ubiquitinated TDP-43
• Size: Typically 5-15 μm in diameter

Neuronal Intranuclear Inclusions (NIIs)

Less common but pathologically significant:

• Morphology: Lentiform or spherical nuclear inclusions
• Frequency: Present in ~20-30% of CBS cases with TDP-43 pathology
• Significance: Often associated with [GRN (Progranulin) gene](/genes/grn) mutations

Glial Inclusions

TDP-43 pathology in CBS can also involve glial cells:

• Astrocytes: TDP-43 positive astrocytes in affected regions
• Oligodendrocytes: Less frequently affected than in [ALS](/diseases/amyotrophic-lateral-sclerosis)
• Microglia: Typically show TDP-43 in cytoplasm during activation

Morphological Subtypes

| Inclusion Type | Frequency in CBS | Similarity to ALS/FTD |
|--------------|------------------|----------------------|
| NCI (Type A) | ~40% | Similar to FTLD-TDP Type A |
| NCI (Type B) | ~30% | Similar to FTLD-TDP Type B |
| NCI (Type C) | ~15% | Similar to FTLD-TDP Type C |
| NII | ~20% | Associated with GRN mutations |

Relationship Between Tau and TDP-43 Pathology

The interaction between tau and TDP-43 pathologies in CBS represents a complex interplay that significantly impacts disease phenotype and progression.

Co-occurrence Patterns

Mechanisms of Tau-TDP-43 Interaction

Spatial Relationship

Studies show distinct patterns of tau and TDP-43 co-localization[@murakami2025][@palleis2025]:

Molecular Cross-talk

Multiple mechanisms link tau and TDP-43 pathologies:

• Phosphorylation Competition: Both proteins compete for kinase/phosphatase activities
• Stress Granule Formation: Tau pathology increases cellular stress, promoting TDP-43 aggregation
• Autophagy Dysfunction: Shared defects in protein clearance pathways
• mitochondrial dysfunction: Both pathologies associated with energy metabolism impairment

Clinical Implications of Mixed Pathology

| Pathology Type | Cognitive Symptoms | Motor Symptoms | Progression |
|---------------|-------------------|---------------|-------------|
| Pure Tau | Mild | Severe | Slower |
| Mixed Tau+TDP-43 | Moderate-Severe | Moderate | Faster |
| Pure TDP-43 | Severe | Moderate | Variable |

TDP-43 Aggregation Mechanisms in CBS

Pathological Cascade

TDP-43 aggregation in CBS follows a multi-step process similar to other TDP-43 proteinopathies:

Key Molecular Steps

1. Nuclear Clearance and Mislocalization

• Stress conditions trigger TDP-43 relocation from nucleus to cytoplasm
• Normal nuclear function (RNA splicing, transcription) is compromised
• Cytoplasmic TDP-43 becomes available for aggregation

2. Post-translational Modifications

• Phosphorylation: Hyperphosphorylation at Ser409/410 and other sites
• Ubiquitination: Tags inclusions for degradation attempts
• SUMOylation: Regulates aggregation propensity
• Cleavage: C-terminal fragments more aggregation-prone

3. Phase Separation and Aggregation

• TDP-43 undergoes liquid-liquid phase separation under stress
• Stress granules serve as nucleation sites
• Progressive conversion to solid aggregates

Factors Promoting Aggregation in CBS

| Factor | Mechanism | Therapeutic Target |
|--------|-----------|-------------------|
| Progranulin deficiency | Loss of neurotrophic support | Recombinant PGRN |
| C9orf72 expansions | DPR toxicity, RNA foci | Antisense oligonucleotides |
| Tau pathology | Cellular stress, shared kinases | Tau-directed therapies |
| Aging | Declining proteostasis | Autophagy enhancers |

Comparison with ALS/FTD TDP-43 Pathology

CBS with TDP-43 pathology shares significant overlap with [ALS](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal dementia](/diseases/frontotemporal-dementia), but exhibits distinct features.

Shared Pathological Features

Both ALS/FTD and CBS show:

• TDP-43 positive cytoplasmic inclusions
• Phosphorylation at Ser409/410
• Nuclear clearance of TDP-43
• Ubiquitination of inclusions
• Similar biochemical properties (C-terminal fragments)

Distinct Features in CBS

| Feature | ALS/FTD | CBS |
|---------|---------|-----|
| Primary proteinopathy | TDP-43 | 4R Tau (usually) |
| Inclusion morphology | Variable | More compact |
| Glial involvement | Extensive | Moderate |
| Motor neuron pathology | Common | Less frequent |
| Spinal cord involvement | Universal | Variable |

Neuroanatomical Patterns

ALS Pattern

• Motor cortex → spinal cord anterior horns
• Prefrontal cortex (FTD)
• Hippocampus (especially in FTD)

CBS Pattern

• Motor cortex (prominent)
• Basal ganglia (prominent)
• Substantia nigra
• Variable hippocampal involvement

Biochemical Differences

| Property | ALS/FTD | CBS-TDP43 |
|----------|---------|-----------|
| Full-length TDP-43 | Present | Present |
| C-terminal fragments | ~45-50 kDa | ~45-50 kDa |
| Phosphorylation pattern | Similar | Similar |
| Solubility | Insoluble | Variable insolubility |

Clinical-Pathological Correlations

The comparison with ALS/FTD has practical implications for CBS[@palleis2025][@tian2024]:

Impact on Neuronal Dysfunction

TDP-43 pathology contributes to neuronal dysfunction in CBS through multiple mechanisms.

Loss of Normal TDP-43 Function

RNA Processing Dysregulation

Nuclear TDP-43 loss causes:

• Alternative splicing alterations (especially in neuronal genes)
• mRNA stability changes
• Transcription dysregulation
• Nuclear envelope integrity issues

Key Affected Pathways

| Pathway | Impact | Consequence |
|---------|--------|-------------|
| Mitochondrial function | Reduced expression | Energy deficit |
| Synaptic proteins | Splicing changes | Synaptic dysfunction |
| Axonal transport | mRNA misregulation | Axonal degeneration |
| Cell survival | Pro-apoptotic changes | Increased cell death |

Gain of Toxic Function

Cytoplasmic TDP-43 aggregates:

Synaptic Dysfunction

TDP-43 pathology significantly impacts synaptic function:

• Presynaptic Effects: Altered neurotransmitter release machinery
• Postsynaptic Effects: Receptor trafficking dysfunction
• Synapse Loss: Correlation with cognitive decline
• Network Dysfunction: Cascading effects on neural circuits

Network-Level Impact

Glial Contributions

TDP-43 in glial cells contributes to neuronal dysfunction:

• Astrocytes: Reduced glutamate uptake, inflammatory activation
• Oligodendrocytes: Myelin dysfunction
• Microglia: Chronic neuroinflammation

Mechanisms of TDP-43 Pathology in CBS

Pathological Mechanisms

The mechanisms linking TDP-43 pathology to CBS include:

Genetic Contributions

Several genetic factors influence TDP-43 pathology in CBS:

• [GRN (Progranulin) Mutations](/genes/grn): Associated with increased TDP-43 pathology
• [C9orf72 Expansions](/genes/c9orf72): Can present with CBS phenotype with TDP-43 pathology
• TMEM106B Variants: Modify TDP-43 pathology risk

TDP-43 Classification Systems

Biomarker-Based Classification

A 2025 study by Palleis et al. established a biomarker-based classification system for CBS that incorporates TDP-43 pathology[@palleis2025]:

| Biomarker Profile | Underlying Pathology | Prevalence |
|------------------|---------------------|------------|
| Tau-positive, TDP-43 negative | Primary 4R tauopathy | ~55% |
| Tau-positive, TDP-43 positive | Mixed tau + TDP-43 | ~30% |
| TDP-43 positive, tau negative | Primary TDP-43opathy | ~15% |

This classification has diagnostic and prognostic implications.

Diagnostic Implications

Clinical-Pathological Correlations

Understanding TDP-43 pathology in CBS has practical implications:

Biomarkers for TDP-43 Pathology

Current and emerging biomarkers include:

• Neurofilament Light Chain (NfL): Elevated in CSF and blood; higher levels in TDP-43 cases
• TDP-43 CSF Levels: Under investigation as direct marker
• PET Tracers: Emerging tau PET may help differentiate pathologies

Therapeutic Implications

Targeting TDP-43 Pathology

Therapeutic strategies for TDP-43 in CBS include[@tian2024]:

Progranulin-Based Therapies

Given the association between [GRN](/genes/grn) mutations and TDP-43 pathology[@gao2024]:

• Recombinant Progranulin: Currently in clinical trials for FTD-GRN
• Gene Therapy: AAV-mediated PGRN delivery under investigation
• Small Molecule Enhancers: Compounds that increase progranulin expression

Relationship to Other CBS Mechanisms

• [LRRK2 in CBS and 4R Tauopathies](/mechanisms/lrrk2-cbs-tauopathies) — Shared mechanisms with other 4R tauopathies
• [CBS vs PSP: Comparative Mechanism Analysis](/mechanisms/cbs-vs-psp-comparison) — TDP-43 frequency differences
• [GRN — Progranulin](/genes/grn) — Genetic factors in TDP-43 pathology
• [C9orf72 Protein](/proteins/c9orf72-protein) — Hexanucleotide expansion mechanisms
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — General TDP-43 mechanisms
• [Progranulin Therapy](/therapeutics/progranulin-therapy) — Therapeutic approaches

Cryo-EM Structure Insights

Recent cryo-electron microscopy studies have provided unprecedented insights into TDP-43 filament structure in CBS and related disorders[@shi2024]. These structural studies reveal:

• Filament Architecture: TDP-43 filaments in CBS show a helical ribbon structure
• Phosphorylation Patterns: Cryo-EM has identified specific phosphorylation sites that stabilize aggregates
• Strain Diversity: Distinct TDP-43 strains may explain phenotypic variability
• Comparison with ALS: CBS TDP-43 filaments show structural similarities to ALS strains

[@shi2024]: [Shi et al., Cryo-EM structure of TDP-43 filaments from frontotemporal lobar degeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

Animal Models of CBS-TDP-43 Pathology

Animal models have been developed to study TDP-43 pathology in CBS context:

Transgenic Models

• TDP-43 Transgenic Mice: Overexpression of mutant TDP-43 recapitulates cytoplasmic inclusions
• GRN Knockout Models: Progranulin-deficient mice show enhanced TDP-43 pathology
• Tau/TDP-43 Cross: Double transgenic mice demonstrate synergistic pathology

Key Findings from Models

| Model | Key Observation | Relevance to CBS |
|-------|-----------------|-----------------|
| TDP-43 A315T | Motor cortex pathology | Motor symptoms |
| GRN-/- | Age-dependent TDP-43 | Genetic forms |
| Tau/P-301L | Accelerated aggregation | Mixed pathology |

These models have identified potential therapeutic targets and are being used for drug screening.

Emerging Biomarkers for CBS-TDP-43

Beyond established biomarkers, several emerging approaches show promise:

Fluid Biomarkers

• Total TDP-43 in CSF: Potential direct marker of pathology
• pTDP-43 Specific Assays: Phosphorylated TDP-43 detection
• Exosomal TDP-43: Neuron-derived exosomes as source

Imaging Biomarkers

• Advanced MRI: Diffusion tensor imaging shows white matter involvement
• PET Tracers: First-generation TDP-43 PET ligands in development
• Structural MRI Patterns: Differentiation of CBS subtypes

Summary

TDP-43 pathology is present in a substantial minority of CBS cases, influencing clinical presentation, disease progression, and therapeutic approaches. The 2025 research by Murakami et al. and others has clarified that:

Understanding the TDP-43 component of CBS is essential for precision medicine approaches to this heterogeneous disorder.

See Also

• [GRN (Progranulin) gene](/genes/grn)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [frontotemporal dementia](/diseases/frontotemporal-dementia)
• [GRN](/genes/grn)
• [C9orf72](/genes/c9orf72)
• [GRN (Progranulin) Mutations](/genes/grn)
• [C9orf72 Expansions](/genes/c9orf72)
• [LRRK2 in CBS and 4R Tauopathies](/mechanisms/lrrk2-cbs-tauopathies)
• [CBS vs PSP: Comparative Mechanism Analysis](/mechanisms/cbs-vs-psp-comparison)
• [GRN — Progranulin](/genes/grn)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References